CPIX — Cumberland Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $127.21m
- $123.01m
- $44.52m
Brief: Cumberland Pharmaceuticals Inc -Vibativ Receives Marketing Approval In China
Brief: Cumberland Pharmaceuticals Announces Phase 2 Fight Dmd Trial Results For Duchenne Muscular Dystrophy Heart Disease
U.S. STOCKS ON THE MOVE-CleanSpark, MoneyLion, CoreCivic
U.S. STOCKS ON THE MOVE-Boeing, Alaska Air, Centene
U.S. STOCKS ON THE MOVE-Oracle, eBay, Pinterest
Cumberland Pharma soars on FDA approval for paracetamol overdose drug
Brief: FDA Approves Acetadote® SNDA
Brief: Cumberland Pharmaceuticals Receives FDA Orphan Drug And Rare Pediatric Disease Designations For New Treatment Of Duchenne Muscular Dystrophy
Brief: Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
Brief: Kazimi Reports 40.14% Passive Stake In Cumberland Pharmaceuticals Inc As Of Dec 31
Brief: Cumberland Pharmaceuticals Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Cumberland Pharmaceuticals Q3 revenue USD 10.1 million.
Brief: Cumberland Pharmaceuticals Inc Entered Into New Revolving Credit Loan Agreement With Pinnacle Bank
Brief: Cumberland Pharmaceuticals Received Consideration Related To Breach Of Contract Action With Melinta Therapeutics & Targanta Therapeutics On June 16
Brief: U.S. FDA Grants Cumberland Pharmaceuticals Barrier-To-Innovation Waiver With Reditrex Product Line
Brief: Cumberland Pharmaceuticals Announces FDA Clearance Of IND For New Treatment Of Idiopathic Pulmonary Fibrosis
Brief: Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update
Brief: Cumberland Pharmaceuticals - Expects Caldolor Injection Product As Eligible For Special Medicare Reimbursement
Brief: Cumberland Pharmaceuticals Reports 17% Revenue Growth For Full Year 2022